http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 03 Jun 2026 16:01:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ProQR+Therapeutics+N.V.+++For%3A+Jun+02++Filed+by%3A+Hinsch+Gylvin+Lykke/26598663.html si-local-file:///var/storage/secattach/20260603/26598663.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ProQR+Therapeutics+N.V.+++For%3A+Jun+02++Filed+by%3A+Hinsch+Gylvin+Lykke/26598663.html Wed, 03 Jun 2026 16:01:00 -0400 O.13108123 PRQR http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ProQR+Therapeutics+N.V.+++For%3A+Jun+02++Filed+by%3A+Hinsch+Gylvin+Lykke/26598663.html si-local-file:///var/storage/secattach/20260603/26598663.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ProQR+Therapeutics+N.V.+++For%3A+Jun+02++Filed+by%3A+Hinsch+Gylvin+Lykke/26598663.html Wed, 03 Jun 2026 16:01:00 -0400 O.13108123 PRQR http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ProQR+Therapeutics+N.V.+++For%3A+Jun+02/26591413.html si-local-file:///var/storage/secattach/20260602/26591413.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ProQR+Therapeutics+N.V.+++For%3A+Jun+02/26591413.html Tue, 02 Jun 2026 16:01:00 -0400 O.13108123 PRQR http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ProQR+Therapeutics+N.V.+++For%3A+Jun+02/26591413.html si-local-file:///var/storage/secattach/20260602/26591413.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ProQR+Therapeutics+N.V.+++For%3A+Jun+02/26591413.html Tue, 02 Jun 2026 16:01:00 -0400 O.13108123 PRQR http://www.streetinsider.com/SEC+Filings/Form++3++++++++++ProQR+Therapeutics+N.V.+++For%3A+Jun+02++Filed+by%3A+Hinsch+Gylvin+Lykke/26591414.html si-local-file:///var/storage/secattach/20260602/26591414.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++ProQR+Therapeutics+N.V.+++For%3A+Jun+02++Filed+by%3A+Hinsch+Gylvin+Lykke/26591414.html Tue, 02 Jun 2026 16:01:00 -0400 O.13108123 PRQR http://www.streetinsider.com/SEC+Filings/Form++3++++++++++ProQR+Therapeutics+N.V.+++For%3A+Jun+02++Filed+by%3A+Hinsch+Gylvin+Lykke/26591414.html si-local-file:///var/storage/secattach/20260602/26591414.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++ProQR+Therapeutics+N.V.+++For%3A+Jun+02++Filed+by%3A+Hinsch+Gylvin+Lykke/26591414.html Tue, 02 Jun 2026 16:01:00 -0400 O.13108123 PRQR http://www.streetinsider.com/Analyst+Comments/ProQR+Therapeutics+N.V.+%28PRQR%29+Reiterated+at+Market+Outperform+by+Citizens+/26552700.html <p>Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $8.00 price target on ProQR Therapeutics N.V. (NASDAQ: PRQR).</p><p>The analyst commented, "After our discussion with Dr. Sokol, we come away with a more nuanced appreciation of the high unmet need in BA, balanced with the consistently challenging drug development track record. While the overall incidence of BA is relatively low (~180-360 U.S. patients/yr) these patients are identified within weeks of birth, are concentrated in specialized centers, and the majority will ultimately progress to liver transplant. Thus, we think patients would likely stay on a safe and effective therapy that could http://www.streetinsider.com/Analyst+Comments/ProQR+Therapeutics+N.V.+%28PRQR%29+Reiterated+at+Market+Outperform+by+Citizens+/26552700.html Wed, 27 May 2026 05:52:12 -0400 PRQR http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ProQR+Therapeutics+N.V.+++For%3A+May+12/26472739.html si-local-file:///var/storage/secattach/20260512/26472739.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ProQR+Therapeutics+N.V.+++For%3A+May+12/26472739.html Tue, 12 May 2026 07:00:00 -0400 O.13108123 PRQR http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ProQR+Therapeutics+N.V.+++For%3A+May+12/26472739.html si-local-file:///var/storage/secattach/20260512/26472739.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ProQR+Therapeutics+N.V.+++For%3A+May+12/26472739.html Tue, 12 May 2026 07:00:00 -0400 O.13108123 PRQR http://www.streetinsider.com/Press+Releases/ProQR+Announces+First+Quarter+2026+Operating+and+Financial+Results/26472744.html <ul type="disc"><li style="margin-bottom:12pt;"> AX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected as initial Phase 2 indication</li><li style="margin-bottom:12pt;">Pipeline expansion with advancement of AX-0811 (NTCP) and AX-0422 (IDUA) toward the clinic, supporting multiple upcoming clinical catalysts</li><li style="margin-bottom:12pt;">Continued advancement of Axiomer platform, including AI-enabled discovery capabilities, partnership with Ginkgo Bioworks, and formation of AI Advisory Board</li><li style="margin-bottom:12pt;">Ended Q1 2026 with € 81.1 million cash and cash equivalents, supporting runway into mid-2027</li></ul> <p>LEIDEN, Netherlands &amp; CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to http://www.streetinsider.com/Press+Releases/ProQR+Announces+First+Quarter+2026+Operating+and+Financial+Results/26472744.html Tue, 12 May 2026 07:00:00 -0400 A.03120574 A.31197700 A.50216777 O.00831659 O.13108123 O.42080841 O.54516537 PRQR http://www.streetinsider.com/Press+Releases/ProQR+Announces+First+Quarter+2026+Operating+and+Financial+Results/26472744.html <ul type="disc"><li style="margin-bottom:12pt;"> AX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected as initial Phase 2 indication</li><li style="margin-bottom:12pt;">Pipeline expansion with advancement of AX-0811 (NTCP) and AX-0422 (IDUA) toward the clinic, supporting multiple upcoming clinical catalysts</li><li style="margin-bottom:12pt;">Continued advancement of Axiomer platform, including AI-enabled discovery capabilities, partnership with Ginkgo Bioworks, and formation of AI Advisory Board</li><li style="margin-bottom:12pt;">Ended Q1 2026 with € 81.1 million cash and cash equivalents, supporting runway into mid-2027</li></ul> <p>LEIDEN, Netherlands &amp; CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to http://www.streetinsider.com/Press+Releases/ProQR+Announces+First+Quarter+2026+Operating+and+Financial+Results/26472744.html Tue, 12 May 2026 07:00:00 -0400 A.03120574 A.31197700 A.50216777 O.00831659 O.13108123 O.42080841 O.54516537 PRQR http://www.streetinsider.com/Press+Releases/ProQR+Announces+First+Quarter+2026+Operating+and+Financial+Results/26472744.html <ul type="disc"><li style="margin-bottom:12pt;"> AX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected as initial Phase 2 indication</li><li style="margin-bottom:12pt;">Pipeline expansion with advancement of AX-0811 (NTCP) and AX-0422 (IDUA) toward the clinic, supporting multiple upcoming clinical catalysts</li><li style="margin-bottom:12pt;">Continued advancement of Axiomer platform, including AI-enabled discovery capabilities, partnership with Ginkgo Bioworks, and formation of AI Advisory Board</li><li style="margin-bottom:12pt;">Ended Q1 2026 with € 81.1 million cash and cash equivalents, supporting runway into mid-2027</li></ul> <p>LEIDEN, Netherlands &amp; CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to http://www.streetinsider.com/Press+Releases/ProQR+Announces+First+Quarter+2026+Operating+and+Financial+Results/26472744.html Tue, 12 May 2026 07:00:00 -0400 A.03120574 A.31197700 A.50216777 O.00831659 O.13108123 O.42080841 O.54516537 PRQR http://www.streetinsider.com/Press+Releases/ProQR+Announces+First+Quarter+2026+Operating+and+Financial+Results/26472744.html <ul type="disc"><li style="margin-bottom:12pt;"> AX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected as initial Phase 2 indication</li><li style="margin-bottom:12pt;">Pipeline expansion with advancement of AX-0811 (NTCP) and AX-0422 (IDUA) toward the clinic, supporting multiple upcoming clinical catalysts</li><li style="margin-bottom:12pt;">Continued advancement of Axiomer platform, including AI-enabled discovery capabilities, partnership with Ginkgo Bioworks, and formation of AI Advisory Board</li><li style="margin-bottom:12pt;">Ended Q1 2026 with € 81.1 million cash and cash equivalents, supporting runway into mid-2027</li></ul> <p>LEIDEN, Netherlands &amp; CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to http://www.streetinsider.com/Press+Releases/ProQR+Announces+First+Quarter+2026+Operating+and+Financial+Results/26472744.html Tue, 12 May 2026 07:00:00 -0400 A.03120574 A.31197700 A.50216777 O.00831659 O.13108123 O.42080841 O.54516537 PRQR http://www.streetinsider.com/Press+Releases/ProQR+Announces+First+Quarter+2026+Operating+and+Financial+Results/26472744.html <ul type="disc"><li style="margin-bottom:12pt;"> AX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected as initial Phase 2 indication</li><li style="margin-bottom:12pt;">Pipeline expansion with advancement of AX-0811 (NTCP) and AX-0422 (IDUA) toward the clinic, supporting multiple upcoming clinical catalysts</li><li style="margin-bottom:12pt;">Continued advancement of Axiomer platform, including AI-enabled discovery capabilities, partnership with Ginkgo Bioworks, and formation of AI Advisory Board</li><li style="margin-bottom:12pt;">Ended Q1 2026 with € 81.1 million cash and cash equivalents, supporting runway into mid-2027</li></ul> <p>LEIDEN, Netherlands &amp; CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to http://www.streetinsider.com/Press+Releases/ProQR+Announces+First+Quarter+2026+Operating+and+Financial+Results/26472744.html Tue, 12 May 2026 07:00:00 -0400 A.03120574 A.31197700 A.50216777 O.00831659 O.13108123 O.42080841 O.54516537 PRQR http://www.streetinsider.com/Press+Releases/ProQR+Announces+First+Quarter+2026+Operating+and+Financial+Results/26472744.html <ul type="disc"><li style="margin-bottom:12pt;"> AX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected as initial Phase 2 indication</li><li style="margin-bottom:12pt;">Pipeline expansion with advancement of AX-0811 (NTCP) and AX-0422 (IDUA) toward the clinic, supporting multiple upcoming clinical catalysts</li><li style="margin-bottom:12pt;">Continued advancement of Axiomer platform, including AI-enabled discovery capabilities, partnership with Ginkgo Bioworks, and formation of AI Advisory Board</li><li style="margin-bottom:12pt;">Ended Q1 2026 with € 81.1 million cash and cash equivalents, supporting runway into mid-2027</li></ul> <p>LEIDEN, Netherlands &amp; CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to http://www.streetinsider.com/Press+Releases/ProQR+Announces+First+Quarter+2026+Operating+and+Financial+Results/26472744.html Tue, 12 May 2026 07:00:00 -0400 A.03120574 A.31197700 A.50216777 O.00831659 O.13108123 O.42080841 O.54516537 PRQR http://www.streetinsider.com/Press+Releases/ProQR+Announces+First+Quarter+2026+Operating+and+Financial+Results/26472744.html <ul type="disc"><li style="margin-bottom:12pt;"> AX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected as initial Phase 2 indication</li><li style="margin-bottom:12pt;">Pipeline expansion with advancement of AX-0811 (NTCP) and AX-0422 (IDUA) toward the clinic, supporting multiple upcoming clinical catalysts</li><li style="margin-bottom:12pt;">Continued advancement of Axiomer platform, including AI-enabled discovery capabilities, partnership with Ginkgo Bioworks, and formation of AI Advisory Board</li><li style="margin-bottom:12pt;">Ended Q1 2026 with € 81.1 million cash and cash equivalents, supporting runway into mid-2027</li></ul> <p>LEIDEN, Netherlands &amp; CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to http://www.streetinsider.com/Press+Releases/ProQR+Announces+First+Quarter+2026+Operating+and+Financial+Results/26472744.html Tue, 12 May 2026 07:00:00 -0400 A.03120574 A.31197700 A.50216777 O.00831659 O.13108123 O.42080841 O.54516537 PRQR http://www.streetinsider.com/Press+Releases/ProQR+Announces+First+Quarter+2026+Operating+and+Financial+Results/26472744.html <ul type="disc"><li style="margin-bottom:12pt;"> AX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected as initial Phase 2 indication</li><li style="margin-bottom:12pt;">Pipeline expansion with advancement of AX-0811 (NTCP) and AX-0422 (IDUA) toward the clinic, supporting multiple upcoming clinical catalysts</li><li style="margin-bottom:12pt;">Continued advancement of Axiomer platform, including AI-enabled discovery capabilities, partnership with Ginkgo Bioworks, and formation of AI Advisory Board</li><li style="margin-bottom:12pt;">Ended Q1 2026 with € 81.1 million cash and cash equivalents, supporting runway into mid-2027</li></ul> <p>LEIDEN, Netherlands &amp; CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to http://www.streetinsider.com/Press+Releases/ProQR+Announces+First+Quarter+2026+Operating+and+Financial+Results/26472744.html Tue, 12 May 2026 07:00:00 -0400 A.03120574 A.31197700 A.50216777 O.00831659 O.13108123 O.42080841 O.54516537 PRQR http://www.streetinsider.com/Globe+Newswire/ProQR+Announces+First+Quarter+2026+Operating+and+Financial+Results/26472744.html <ul type="disc"><li style="margin-bottom:12pt;"> AX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected as initial Phase 2 indication</li><li style="margin-bottom:12pt;">Pipeline expansion with advancement of AX-0811 (NTCP) and AX-0422 (IDUA) toward the clinic, supporting multiple upcoming clinical catalysts</li><li style="margin-bottom:12pt;">Continued advancement of Axiomer platform, including AI-enabled discovery capabilities, partnership with Ginkgo Bioworks, and formation of AI Advisory Board</li><li style="margin-bottom:12pt;">Ended Q1 2026 with € 81.1 million cash and cash equivalents, supporting runway into mid-2027</li></ul> <p>LEIDEN, Netherlands &amp; CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to http://www.streetinsider.com/Globe+Newswire/ProQR+Announces+First+Quarter+2026+Operating+and+Financial+Results/26472744.html Tue, 12 May 2026 07:00:00 -0400 A.03120574 A.31197700 A.50216777 O.00831659 O.13108123 O.42080841 O.54516537 PRQR http://www.streetinsider.com/Globe+Newswire/ProQR+Announces+First+Quarter+2026+Operating+and+Financial+Results/26472744.html <ul type="disc"><li style="margin-bottom:12pt;"> AX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected as initial Phase 2 indication</li><li style="margin-bottom:12pt;">Pipeline expansion with advancement of AX-0811 (NTCP) and AX-0422 (IDUA) toward the clinic, supporting multiple upcoming clinical catalysts</li><li style="margin-bottom:12pt;">Continued advancement of Axiomer platform, including AI-enabled discovery capabilities, partnership with Ginkgo Bioworks, and formation of AI Advisory Board</li><li style="margin-bottom:12pt;">Ended Q1 2026 with € 81.1 million cash and cash equivalents, supporting runway into mid-2027</li></ul> <p>LEIDEN, Netherlands &amp; CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to http://www.streetinsider.com/Globe+Newswire/ProQR+Announces+First+Quarter+2026+Operating+and+Financial+Results/26472744.html Tue, 12 May 2026 07:00:00 -0400 A.03120574 A.31197700 A.50216777 O.00831659 O.13108123 O.42080841 O.54516537 PRQR http://www.streetinsider.com/Globe+Newswire/ProQR+Announces+First+Quarter+2026+Operating+and+Financial+Results/26472744.html <ul type="disc"><li style="margin-bottom:12pt;"> AX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected as initial Phase 2 indication</li><li style="margin-bottom:12pt;">Pipeline expansion with advancement of AX-0811 (NTCP) and AX-0422 (IDUA) toward the clinic, supporting multiple upcoming clinical catalysts</li><li style="margin-bottom:12pt;">Continued advancement of Axiomer platform, including AI-enabled discovery capabilities, partnership with Ginkgo Bioworks, and formation of AI Advisory Board</li><li style="margin-bottom:12pt;">Ended Q1 2026 with € 81.1 million cash and cash equivalents, supporting runway into mid-2027</li></ul> <p>LEIDEN, Netherlands &amp; CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to http://www.streetinsider.com/Globe+Newswire/ProQR+Announces+First+Quarter+2026+Operating+and+Financial+Results/26472744.html Tue, 12 May 2026 07:00:00 -0400 A.03120574 A.31197700 A.50216777 O.00831659 O.13108123 O.42080841 O.54516537 PRQR http://www.streetinsider.com/Globe+Newswire/ProQR+Announces+First+Quarter+2026+Operating+and+Financial+Results/26472744.html <ul type="disc"><li style="margin-bottom:12pt;"> AX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected as initial Phase 2 indication</li><li style="margin-bottom:12pt;">Pipeline expansion with advancement of AX-0811 (NTCP) and AX-0422 (IDUA) toward the clinic, supporting multiple upcoming clinical catalysts</li><li style="margin-bottom:12pt;">Continued advancement of Axiomer platform, including AI-enabled discovery capabilities, partnership with Ginkgo Bioworks, and formation of AI Advisory Board</li><li style="margin-bottom:12pt;">Ended Q1 2026 with € 81.1 million cash and cash equivalents, supporting runway into mid-2027</li></ul> <p>LEIDEN, Netherlands &amp; CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to http://www.streetinsider.com/Globe+Newswire/ProQR+Announces+First+Quarter+2026+Operating+and+Financial+Results/26472744.html Tue, 12 May 2026 07:00:00 -0400 A.03120574 A.31197700 A.50216777 O.00831659 O.13108123 O.42080841 O.54516537 PRQR http://www.streetinsider.com/Globe+Newswire/ProQR+Announces+First+Quarter+2026+Operating+and+Financial+Results/26472744.html <ul type="disc"><li style="margin-bottom:12pt;"> AX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected as initial Phase 2 indication</li><li style="margin-bottom:12pt;">Pipeline expansion with advancement of AX-0811 (NTCP) and AX-0422 (IDUA) toward the clinic, supporting multiple upcoming clinical catalysts</li><li style="margin-bottom:12pt;">Continued advancement of Axiomer platform, including AI-enabled discovery capabilities, partnership with Ginkgo Bioworks, and formation of AI Advisory Board</li><li style="margin-bottom:12pt;">Ended Q1 2026 with € 81.1 million cash and cash equivalents, supporting runway into mid-2027</li></ul> <p>LEIDEN, Netherlands &amp; CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to http://www.streetinsider.com/Globe+Newswire/ProQR+Announces+First+Quarter+2026+Operating+and+Financial+Results/26472744.html Tue, 12 May 2026 07:00:00 -0400 A.03120574 A.31197700 A.50216777 O.00831659 O.13108123 O.42080841 O.54516537 PRQR http://www.streetinsider.com/Globe+Newswire/ProQR+Announces+First+Quarter+2026+Operating+and+Financial+Results/26472744.html <ul type="disc"><li style="margin-bottom:12pt;"> AX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected as initial Phase 2 indication</li><li style="margin-bottom:12pt;">Pipeline expansion with advancement of AX-0811 (NTCP) and AX-0422 (IDUA) toward the clinic, supporting multiple upcoming clinical catalysts</li><li style="margin-bottom:12pt;">Continued advancement of Axiomer platform, including AI-enabled discovery capabilities, partnership with Ginkgo Bioworks, and formation of AI Advisory Board</li><li style="margin-bottom:12pt;">Ended Q1 2026 with € 81.1 million cash and cash equivalents, supporting runway into mid-2027</li></ul> <p>LEIDEN, Netherlands &amp; CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to http://www.streetinsider.com/Globe+Newswire/ProQR+Announces+First+Quarter+2026+Operating+and+Financial+Results/26472744.html Tue, 12 May 2026 07:00:00 -0400 A.03120574 A.31197700 A.50216777 O.00831659 O.13108123 O.42080841 O.54516537 PRQR http://www.streetinsider.com/Globe+Newswire/ProQR+Announces+First+Quarter+2026+Operating+and+Financial+Results/26472744.html <ul type="disc"><li style="margin-bottom:12pt;"> AX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected as initial Phase 2 indication</li><li style="margin-bottom:12pt;">Pipeline expansion with advancement of AX-0811 (NTCP) and AX-0422 (IDUA) toward the clinic, supporting multiple upcoming clinical catalysts</li><li style="margin-bottom:12pt;">Continued advancement of Axiomer platform, including AI-enabled discovery capabilities, partnership with Ginkgo Bioworks, and formation of AI Advisory Board</li><li style="margin-bottom:12pt;">Ended Q1 2026 with € 81.1 million cash and cash equivalents, supporting runway into mid-2027</li></ul> <p>LEIDEN, Netherlands &amp; CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to http://www.streetinsider.com/Globe+Newswire/ProQR+Announces+First+Quarter+2026+Operating+and+Financial+Results/26472744.html Tue, 12 May 2026 07:00:00 -0400 A.03120574 A.31197700 A.50216777 O.00831659 O.13108123 O.42080841 O.54516537 PRQR http://www.streetinsider.com/Globe+Newswire/ProQR+Announces+First+Quarter+2026+Operating+and+Financial+Results/26472744.html <ul type="disc"><li style="margin-bottom:12pt;"> AX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected as initial Phase 2 indication</li><li style="margin-bottom:12pt;">Pipeline expansion with advancement of AX-0811 (NTCP) and AX-0422 (IDUA) toward the clinic, supporting multiple upcoming clinical catalysts</li><li style="margin-bottom:12pt;">Continued advancement of Axiomer platform, including AI-enabled discovery capabilities, partnership with Ginkgo Bioworks, and formation of AI Advisory Board</li><li style="margin-bottom:12pt;">Ended Q1 2026 with € 81.1 million cash and cash equivalents, supporting runway into mid-2027</li></ul> <p>LEIDEN, Netherlands &amp; CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to http://www.streetinsider.com/Globe+Newswire/ProQR+Announces+First+Quarter+2026+Operating+and+Financial+Results/26472744.html Tue, 12 May 2026 07:00:00 -0400 A.03120574 A.31197700 A.50216777 O.00831659 O.13108123 O.42080841 O.54516537 PRQR